Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

Biological Psychiatry

Volumn 55, Issue 5, 2004, Pages 452-456

  Tsai, Guochuan ^a   Lane, Hsien Yuan ^b   Yang, Pinchen ^c   Chong, Mian Yoon ^c   Lange, Nicholas ^a  

^a MCLEAN HOSPITAL   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Glutamate; GlyT 1; N methyl D aspartate; Sarcosine; Schizophrenia; Treatment

Indexed keywords

AMINO ACID DERIVATIVE; CHLORPROMAZINE; CLOTIAPINE; FLUPHENAZINE DECANOATE; GLYCINE TRANSPORTER 1 INHIBITOR; HALOPERIDOL; NEUROLEPTIC AGENT; PIPOTIAZINE; RISPERIDONE; SARCOSINE; SULPIRIDE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMIC DISEASE; TACHYCARDIA; TREATMENT OUTCOME; TREMOR;

ADULT; AFFECTIVE SYMPTOMS; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE; SARCOSINE; SCHIZOPHRENIA;

EID: 1542617755     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2003.09.012     Document Type: Article

References (41)

1. American Psychiatric Association (1994a): Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press.
2. American Psychiatric Association (1994b): Structured Clinical Interview for DSM-IV. Washington, DC: American Psychiatric Press.
3. Andreasen N.C. Scales for the Assessment of Negative Symptoms (SANS). 1983;University of Iowa, Iowa City, IA.
4. Barnes T.R.E. A rating scale for the drug-induced akathesia. Br J Psychiatry. 154:1989;672-676.
5. Bergeron R., Meyer T., Coyle J., Greene R. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A. 95:1998;15730-15734.
6. Bergeron F., Otto A., Blache P., Day R., Denoroy L., Brandsch R., et al. Molecular cloning and tissue distribution of rat sarcosine dehydrogenase. Eur J Biochem. 257:1998;556-561.
7. Chen L., Muhlhauser M., Yang C.R. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol. 89:2003;691-703.
8. Cook S.P., Galve-Roperh I., del Pozo A.M., Rodriguez-Crespo I. Direct calcium binding results in activation of brain serine racemase. J Biol Chem. 277:2002;27782-27792.
9. Eschenbrenner M., Jorns M.S. Cloning and mapping of the cDNA for human sarcosine dehydrogenase, a flavoenzyme defective in patients with sarcosinemia. Genomics. 59:1999;300-308.
10. Farber N.B., Newcomer J., Olney J.W. Glycine agonists What can they teach us about schizophrenia? Arch Gen Psychiatry. 56:1999;13-17.
11. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 56:1999;21-27.
12. Grotta J. Safety and tolerability of the glutamate antagonist CGS 19755 in acute stroke patients. Stroke. 25:1994;255.
13. Guy W, editor (1997): ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, 534-537.
14. Halberstadt A.L. The phencyclidine-glutamate model of schizophrenia. Clin Neuropharmacol. 18:1995;237-249.
15. Hamilton M. A rating scale of depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
16. Harding C.O., Williams P., Pflanzer D.M., Colwell R.E., Lyne P.W., Wolff J.A. Sar A genetic mouse model for human sarcosinemia generated by ethylnitrosourea mutagenesis. Proc Natl Acad Sci U S A. 89:1992;2644-2648.
17. Heresco-Levy U., Ermilov M., Shimoni J., Shapira B., Silipo G., Javitt D.C. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry. 159:2002;480-482.
18. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 169:1996;610-617.
19. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 56:1999;29-36.
20. Heresco-Levy U., Silipo G., Javitt D.C. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull. 32:1996;731-740.
21. Herrling P.L. D-CPPene (SDZ EAA 494), a competitive NMDA antagonist Results from animal models and first results in humans. Neuropsychopharmacology. 10:(suppl 3):1994;591S.
22. Javitt D.C., Balla A., Sershen H., Lajtha A. A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry. 45:1999;668-679.
23. Javitt D.C., Silipo G., Cienfuegos A., Shelley A.M., Bark N., Park M., et al. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol. 4:2001;385-391.
24. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
25. Kay S.R., Opler L.A., Fiszbein A. Positive and negative syndrome scale (PANSS) manual. Schizophr Bull. 13:1987;261-276.
26. Kristensen J.D., Svensson B., Gordh T. The NMDA receptor antagonist CPP abolishes neurogenic 'wind up pain' after intrathecal administration in humans. Pain. 51:1992;249-253.
27. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 51:1994;199-214.
28. Lange N., Ryan L. Assessing normality in random effects models. Ann Stat. 17:1989;624-642.
29. Levy H.L., Coulombe J.T., Benjamin R. Massachusetts metabolic disorders screening program III. Sarcosinemia Pediatr. 74:1984;509-513.
30. Lindenmayer J.P., Bernstein-Hyman R., Grochowski S. Five factor model of schizophrenia. Initial validation. J Nerv Ment Dis. 182:1994;631-638.
31. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU Side Effect Rating Scale A new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 334:1987;1-100.
32. McBain C.J., Kleckner N.W., Wyrick S., Dingledine R. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in xenopus oocytes. Mol Pharmacol. 36:1989;556-565.
33. McDonald J.W., Johnston M.V. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev. 15:1990;41-70.
34. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 52:1995;998-1007.
35. Simpson GM, Angus JWS (1970b): A rating scale for extrapyramidal side effects.Acta Psychiatry Scand Suppl 212:11-19.
36. Smith K.E., Borden L.A., Hartig P.R., Branchek T., Weinshank R.L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron. 8:1992;927-935.
37. Thomson A.M., Walker V.E., Flynn D.M. Glycine enhances NMDA-receptor mediated synatic potentials in neocortical slices. Nature. 338:1989;422-424.
38. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 42:2001;165-179.
39. Tsai G., van Kammen D., Chen S., Kelley M.E., Coyle J.T. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry. 44:1998;667-674.
40. Tsai G., Yang P., Chung L., Lange N., Coyle J.T. D-serine added to antipsychotic for the treatment of schizophrenia. Biol Psychiatry. 44:1998;1081-1089.
41. van Berckel B.N.M., Hijman R., van der Linder J.A., Westerberg H.G.M., van Ree J.M., Kahn R.S. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry. 40:1996;1298-1300.